



(12) Translation of  
European patent specification

(11) NO/EP 3743091 B1

NORWAY

(19) NO  
(51) Int Cl.  
**A61K 38/00 (2006.01)**  
**C07K 14/71 (2006.01)**

**Norwegian Industrial Property Office**

|      |                                                                            |                                                                                                                                                                                                   |
|------|----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (45) | Translation Published                                                      | 2025.01.27                                                                                                                                                                                        |
| (80) | Date of The European<br>Patent Office Publication of<br>the Granted Patent | 2024.11.06                                                                                                                                                                                        |
| (86) | European Application Nr.                                                   | 19744016.7                                                                                                                                                                                        |
| (86) | European Filing Date                                                       | 2019.01.25                                                                                                                                                                                        |
| (87) | The European Application's<br>Publication Date                             | 2020.12.02                                                                                                                                                                                        |
| (30) | Priority                                                                   | 2018.01.26, US, 201862622382 P                                                                                                                                                                    |
| (84) | Designated Contracting<br>States:                                          | AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ;<br>IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ;<br>SK ; SM ; TR |
| (73) | Proprietor                                                                 | The Regents of the University of California, 1111 Franklin Street, 5th Floor,<br>Oakland, CA 94607-5200, USA                                                                                      |
| (72) | Inventor                                                                   | FERRARA, Napoleone, 9500 Gilman Drive, La Jolla, California 92093-0910, USA                                                                                                                       |
| (74) | Agent or Attorney                                                          | BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge                                                                                                                                                |

|      |                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|------|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (54) | Title                | <b>METHODS AND COMPOSITIONS FOR TREATMENT OF ANGIOGENIC DISORDERS USING<br/>ANTI-VEGF AGENTS</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| (56) | References<br>Cited: | CN-A- 1 793 179<br>WO-A1-2015/000181<br>WO-A1-2017/001990<br>US-A1- 2003 017 977<br>US-A1- 2008 292 628<br>US-A1- 2015 175 675<br>US-A1- 2016 024 483<br>US-A1- 2017 342 127<br>US-A1- 2017 305 996<br>J.-E. LEE ET AL: "Novel Glycosylated VEGF Decoy Receptor Fusion Protein, VEGF-Grab,<br>Efficiently Suppresses Tumor Angiogenesis and Progression", MOLECULAR CANCER<br>THERAPEUTICS, vol. 14, no. 2, 22 December 2014 (2014-12-22), US, pages 470 - 479,<br>XP055224938, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-14-0968-T<br>"Adeno-Associated Virus Serotype 6 (AAV-6) Vector Mediated Gene Transfer of Soluble VEGF<br>Receptors for the Treatment of Glioblastoma Multiforme", MOLECULAR THERAPY, ELSEVIER<br>INC, US, vol. 9, 1 May 2004 (2004-05-01), pages 405 - 406, XP004635424, ISSN: 1525-0016<br>SANJUKTA CHAKRABARTI ET AL: "Studies to Prevent Degradation of Recombinant Fc-Fusion<br>Protein Expressed in Mammalian Cell Line and Protein Characterization", INTERNATIONAL<br>JOURNAL OF MOLECULAR SCIENCES, vol. 17, no. 6, 9 June 2016 (2016-06-09), pages 1 -<br>22, XP055376196, DOI: 10.3390/ijms17060913<br>K. BAILEY FREUND ET AL: "Aflibercept: a review of its use in the treatment of choroidal<br>neovascularization due to age-related macular degeneration", CLINICAL OPHTHALMOLOGY, 1<br>December 2015 (2015-12-01), pages 2355, XP055359313, DOI: 10.2147/OPTH.S80040 |

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

**Patentkrav**

- 1.** Et anti-VEGF-middel bestående av aminosyrer 27 til 459 av SEKV ID NR: 3 for bruk i behandling av neovaskulær aldersrelatert makuladegenerasjon.
- 2.** Anti-VEGF-middel for bruk ifølge krav 1, hvori anti-VEGF-midlet har en glasslegeme-bundet VEGF-stimulert endotelcelleproliferasjonsinhiberende evne som er større enn aflibercept.
- 3.** Anti-VEGF-middel for anvendelse ifølge krav 1 eller 2, hvori anti-VEGF-midlet har en lengre varighet etter intravitreal administrering sammenlignet med aflibercept.
- 4.** Anti-VEGF-middel for anvendelse ifølge hvilket som helst av kravene 1-3, hvori anti-VEGF-midlet er formulert for en intravitreal injeksjon.